medigraphic.com
ISSN 2225-4676 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cubana Neurol Neurocir 2014; 4 (2)

Adverse reactions to antiepileptic drugs reported in Bogota (Colombia, 2008–2012)

Chaves TNM, Quijano RJJ

Language: Spanish
References: 30
Page: 117-123
PDF size: 277.14 Kb.


ABSTRACT

Objective: To characterize adverse reactions to antiepileptic drugs occurred in Bogotá D.C. population reported to the District Pharmacovigilance Program between January 2008 and December 2012.
Methods: A descriptive pharmacovigilance study was carried out with reports of adverse events and problems associated with the use of antiepileptic drugs entered in the database of Bogotá D.C. District Pharmacovigilance Program.
Results: 173 reports of suspected adverse events and problems associated with the use of antiepileptic drugs in the population of Bogotá were evaluated. Of which 126 reports (72.8 %) were classified as suspected adverse drug reports and 20 reports (11.5 %) as problems related with drugs use. Antiepileptic drug with more number of notifications was carbamazepine with 41 notifications (23.7 %), followed by phenytoin with 40 notifications (23.1 %). The organ system most affected by adverse drug reactions was skin and it´s appendages (24.3 %). Regarding evaluation of reaction severity, most reports were for moderate adverse reaction suspected (43 %). With regard to causality most suspected adverse reactions were classified as possible (83 %).
Conclusions: The behavior of adverse reactions reported to antiepileptic drugs notified in District Pharmacovigilance Program of Bogotá, Colombia during 2008–2012 was similar with literature descriptions for each of the drugs included in antiepileptic’s group. The drug that reached the highest percentage of notifications as adverse reactions was carbamazepine.


REFERENCES

  1. López E, Bravo J, Solís H. Epilepsia y antiepilépticos de primera y segunda generación. Aspectos básicos útiles en la práctica clínica. Rev Fac Med UNAM. Sep–Oct 2005;48(5):201–9.

  2. Gil Nagel A, García I. Etiopatogenia y fisiopatología de la epilepsia. Medicine. 2007;9(75):4806–13.

  3. Eslava J, Espinosa E, Izquierdo A, Medina–Malo C, Nariño D, Carreño O. Consenso Colombiano de Epilepsia 2006. Acta Neurol Colomb. 2006;22:365–404.

  4. Medel JS, Ramos FR, Correa J, Cruz JS, Virginia M, Velásquez V. Participación de los canales de calcio dependientes de voltaje en el desarrollo de la epilepsia. Acta Bioquím Clín Latinoam. 2010;44(3):329–35.

  5. Velez A, Eslava–Cobos J. Epilepsy in Colombia: epidemiologic profile and classification of epileptic seizures and syndromes. Epilepsia. 2006;47(1):193–201.

  6. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10:446–56.

  7. Riverol M, Gómez–Ibáñez A, Carmona M. Avances en el tratamiento de la epilepsia. Medicine. 2009;10(46):3091–9.

  8. Dieter Schmidt. Drug treatment of epilepsy: Options and limitations. Epilepsy Behav. 2009;15:56–65.

  9. Hirsch JL, Gaspar N. Status Epilepticus. Continuum (Minneap Minn). 2013;19(3):767–94.

  10. Cárdenas C, Arellano J, Alfaro P, Faúndez E, Le–Bert M, Calderón P, Molgó M, Chávez P. Protocolo de Farmacovigilancia a Reacciones de Hipersensibilidad a Medicamentos: Resultados de su aplicación en cinco centros de Santiago. Rev Chilena Dermatol. 2010;26(2):131–7.

  11. Ferner R, Butt TF. Adverse drug reactions. Medicine. 2012;40(7):366–70.

  12. Farcas A, Sinpetrean B, Mogosan C, Palage M, Vostinaru O, Bojita M, Dumitrascu D. Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in Romania. Eur J Intern Med. 2010;21:453–7.

  13. Hazell L, Shakir S. Under–Reporting of Adverse Drug Reactions: A Systematic Review. Drug Saf. 2006;29(5):385–96.

  14. The Nordic Council on Medicines Working Group concerning ATC/DDD questions. Guidelines for ATC classification and DDD assignment. Oslo. Nordic Council on Medicines and WHO Collaborating Centre for Drug Statistics methodology. [Internet] 2011. [citado 2 mayo 2013]. Disponible en http://www.whocc.no/filearchive/publications/2011guidelines.pdf

  15. Valsecia M. Farmacovigilancia y mecanismos de reacciones adversas a medicamentos. En: Farmacología Médica [Internet] 2000 [citado 4 de abril 2005] 5(13):135–48. Disponible en: http://med.unne.edu.ar/inicio.htm

  16. Holloway K, Green T, World Health Organization. Dept. of Essential Drugs and Medicines Policy. Comités de farmacoterapia: Guía práctica. Geneva: World Health Organization. 2003. p. 155.

  17. Grupo de Farmacovigilancia de la Red Panamericana para la Armonización Farmacéutica (PARF) de la Organización Panamericana de la Salud (OPS). Buenas prácticas de farmacovigilancia para las Américas. [Internet]. 2008 [citado 01 Dic 2013]. Disponible en: http://apps.who.int/medicinedocs/documents/s18625es/s18625es.pdf

  18. Rodríguez Clavijo BD. Farmacovigilancia intensiva en pacientes pediátricos con epilepsia focal tratados con carbamazepina en monoterapia. Maestría de tesis. Universidad Nacional de Colombia, 2010.

  19. Andrade Machado R, Goicoechea Astencio A, Rodríguez García PL, Fernández Abreu Z, Santos Santos A, Garnier Ávila T, et al. Guías de prácticas clínicas para la atención y el manejo de los problemas médicos de las mujeres con epilepsia. Rev Cubana Neurol Neurocir. [Internet] 2013 [citado 01 Dic 2013];3(2):172–95. Disponible en: http://www.revneuro.sld.cu/index.php/neu/article/view/163

  20. Comité de Epilepsia Asociación Colombiana de Neurología. Consenso Colombiano de Epilepsia 2006. Acta Neurol Colomb. 2006;22(4):366–83.

  21. Baroni E, Leroux MB, Sánchez A, Fernández R. Síndrome de hipersensibilidad a anticonvulsivantes. Rev Argent Dermatol. 2007;88:46–54.

  22. Manuela G, Lawrence C, Radu M, Paul AH. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Transl Res. 2012 May;159(5):397–406.

  23. Alvestad S, Lydersen S, Brodtkorb E. Rash from Antiepileptic Drugs: Influence by Gender, Age, and Learning Disability. Epilepsia. 2007;48(7):1360–5.

  24. Durán M, Danés I. Síndrome de hipersensibilidad por antiepilépticos. Med Clin Barc. 2001;116:155–6.

  25. Mayorga C, Sanz ML, Gamboa P, Garcia–Aviles MC, Fernandez J, Torres MJ. Spanish Society of Allergy and Clinical; Immunology; Immunology and Drug Allergy Committee. J Investig Allergol Clin Immunol. 2013;23(4):213–25.

  26. Wang X, Lang SY, Shi SB, Tian HJ, Wang RF, Yang F. Antiepileptic drug–induced skin reactions: A retrospective study and analysis in 3793 Chinese patients with epilepsy. Clin Neurol Neurosurg. 2012;114:862–5.

  27. Brodtkorba E, Alvestada S, Lydersenb S. Cross–reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 2008;80:194–200.

  28. Clemens B, Ménes A, Piros P, Bessenyei M, Altmann A, Jerney J, et al. Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. Epilepsy Res. 2006;70:190–9.

  29. Menachem B. Strategy for utilization of new antiepileptic drugs. Curr Opin Neurol. 2008;21:167–72.

  30. Parveen S, Javed MA. Stevens Johnson Syndrome associated with Lamotrigine. Pak J Med Sci. 2013 Nov;29(6):1450–2.




2020     |     www.medigraphic.com